Home/Filings/4/0001867096-25-000138
4//SEC Filing

HALKUFF DAWN 4

Accession 0001867096-25-000138

CIK 0001867096other

Filed

Aug 12, 8:00 PM ET

Accepted

Aug 13, 4:47 PM ET

Size

6.1 KB

Accession

0001867096-25-000138

Insider Transaction Report

Form 4
Period: 2025-08-12
HALKUFF DAWN
Director
Transactions
  • Sale

    Common Stock

    2025-08-12$7.28/sh42,500$309,226115,000 total
Holdings
  • Common Stock

    (indirect: By Trust)
    5,410
Footnotes (2)
  • [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.190 to $7.450, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F2]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Issuer

Xeris Biopharma Holdings, Inc.

CIK 0001867096

Entity typeother

Related Parties

1
  • filerCIK 0001743658

Filing Metadata

Form type
4
Filed
Aug 12, 8:00 PM ET
Accepted
Aug 13, 4:47 PM ET
Size
6.1 KB